TP53 and B-cell chronic lymphocytic leukemia: Significantly inferior PFS was observed with CD49d+ CLL compared with CD49d− CLL (Fig. 7 A and Table 1), whereas among the other variables, only TP53 disruption, IGHV gene mutations, and the TN/RR status predicted shorter PFS, in keeping with previously reported observations (Byrd et al., 2015; Ahn et al., 2017; Fig. 7, B–D; and Table 1).